Results 151 to 160 of about 3,401,781 (173)
Some of the next articles are maybe not open access.
Blood, 2023
Background: Epcoritamab SC, a CD3xCD20 T-cell-engaging bispecific antibody, has recently been approved by the US FDA for the treatment of adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥2 lines of ...
Julie M. Vose +19 more
openaire +1 more source
Background: Epcoritamab SC, a CD3xCD20 T-cell-engaging bispecific antibody, has recently been approved by the US FDA for the treatment of adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥2 lines of ...
Julie M. Vose +19 more
openaire +1 more source
Consensus on cytokine release syndrome (CRS) monitoring practices: A Delphi approach
BloodAbstract Background Cytokine release syndrome (CRS) is a well-known and potentially fatal side effect of T cell redirecting therapy including therapies with chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engagers (TCE) (Kanate, 2023 & Kanate, 2020).
Elisabeth Piault-Louis +11 more
openaire +1 more source
Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR.
Journal of Clinical Oncology, 20163040Background: Cytokine release syndrome (CRS) is observed with adoptive T-cell therapies (ACT) with varying frequency. CRS can be life threatening and may require steroids, which hinder the effectiveness of ACT. CRS prevalence and severity within the context NY-ESO-1C259T across 5 studies in 4 tumor types were examined: synovial sarcoma (SS), ovarian
Crystal Mackall +11 more
openaire +1 more source
Management of Cytokine Release Syndrome (CRS) Following CAR T-Cell Therapy: A Comprehensive Review
Abstract Chimeric antigen receptor T-cell (CAR T-cell) therapy represents a paradigm shift in treating refractory hematological malignancies. Despite its transformative potential, clinical application is frequently complicated by severe, potentially life-threatening toxicities, with cytokine release syndrome (CRS) being the most ...
Yajing Zhang, Weidong Han
exaly +2 more sources
Blood
Background Cancer immunotherapies such as chimeric antigen receptor (CAR) T cell therapies and bispecific antibodies are highly effective treatments for patients with haematological malignancies.
Liam Tremble +8 more
openaire +1 more source
Background Cancer immunotherapies such as chimeric antigen receptor (CAR) T cell therapies and bispecific antibodies are highly effective treatments for patients with haematological malignancies.
Liam Tremble +8 more
openaire +1 more source
Blood
Abstract Introduction: Talquetamab (tal), a GPRC5D-targeting bispecific antibody (bsAb), is approved for treatment of relapsed/refractory multiple myeloma (RRMM). CRS is commonly associated with tal, occurring in up to 80% of patients in the MonumenTAL-1 study.
Jessica McElwee +25 more
openaire +1 more source
Abstract Introduction: Talquetamab (tal), a GPRC5D-targeting bispecific antibody (bsAb), is approved for treatment of relapsed/refractory multiple myeloma (RRMM). CRS is commonly associated with tal, occurring in up to 80% of patients in the MonumenTAL-1 study.
Jessica McElwee +25 more
openaire +1 more source
Cytokine Release Syndrome (CRS)- Severity grading criteria and it’s management modalities
2023Tushar Roy, Nipom Deka
openaire +1 more source
Expert Opinion on Biological Therapy, 2023
Gabrielle, Leclercq-Cohen +2 more
openaire +2 more sources
Gabrielle, Leclercq-Cohen +2 more
openaire +2 more sources
Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL
Blood, 2022Shakthi Bhaskar +13 more
openaire +1 more source
The Deregulated Immune Reaction and Cytokines Release Storm (CRS) in COVID-19 Disease
International Immunopharmacology, 2021Ritu Pasrija
exaly

